PeptidePedia The community reference

Contributions of AmylinAmos

User contributions·43 logged edits·page 1 of 1

Contributions by AmylinAmos, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 6,249 edits includes activity predating the current log.

  1. 01:43, 24 Jul 2026 (diff | hist) Asymchem Laboratories 6,337 +331 m typo
  2. 08:33, 12 Jul 2026 (diff | hist) Incretin effect 7,358 ±0 m give the fasting and postprandial concentrations with the assay named
  3. 01:10, 19 Jun 2026 (diff | hist) Amylin receptor agonist 5,245 ±0 state the substitution in one-letter code as well, per PP:MOS
  4. 11:46, 17 Jun 2026 (diff | hist) Peptide content 8,404 ±0 expand §How content is determined
  5. 04:40, 25 May 2026 (diff | hist) Proglucagon 6,709 ±0 ce, tighten prose
  6. 09:49, 24 May 2026 (diff | hist) Lyophilisation 28,679 ±0 m the article confused primary and secondary drying; corrected
  7. 10:30, 16 Apr 2026 (diff | hist) Talk:Amylin receptor agonist 400 +273 /* Calcitonin receptor cross-activity */ new section
  8. 09:05, 12 Mar 2026 (diff | hist) Talk:Amylin 822 +93 /* Amyloid: cause or consequence? */ reply
  9. 10:15, 11 Mar 2026 (diff | hist) Talk:Amylin 400 +215 /* Amyloid: cause or consequence? */ new section
  10. 13:15, 5 Mar 2026 (diff | hist) Talk:Cagrilintide 611 +105 /* Calcitonin receptor engagement */ reply
  11. 19:38, 3 Mar 2026 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 m clarify that the receptor is expressed outside the pancreas
  12. 07:09, 25 Feb 2026 (diff | hist) Guangzhou JEEP Biotechnology 15,452 ±0 add category for suppliers in China
  13. 10:02, 9 Feb 2026 (diff | hist) Incretin effect 7,358 ±0 m add the reference range with the assay it was established on
  14. 13:33, 29 Jan 2026 (diff | hist) Liquid chromatography-mass spectrometry 4,463 ±0 correct the flow rate — the source gives it in mL/min
  15. 16:43, 26 Jan 2026 (diff | hist) GLP-1 receptor 7,570 ±0 British spelling per PP:MOS
  16. 13:55, 17 Jan 2026 (diff | hist) Talk:Peptide aggregation 611 +128 /* Reversible versus irreversible */ reply
  17. 07:37, 1 Dec 2025 (diff | hist) Insulin syringe unit conversion 6,290 ±0 m add the trial and year to each row of the comparison
  18. 13:22, 26 Oct 2025 (diff | hist) Receptor bias 4,477 ±0 add the counter-regulatory glucagon point, sourced
  19. 13:14, 13 Oct 2025 (diff | hist) Beta cell function 6,096 ±0 move the trial material out of §Physiology into the compound articles
  20. 02:47, 15 Sep 2025 (diff | hist) Hypoglycaemia 4,473 +56 rm a duplicated category
  21. 02:29, 4 Sep 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 add category for receptor pharmacology
  22. 15:08, 27 Aug 2025 (diff | hist) Receptor bias 4,477 +477 m expand §Status of the idea
  23. 02:20, 1 Aug 2025 (diff | hist) Incretin effect 7,134 ±0 m attribute the receptor-density claim to the tissue study it comes from
  24. 07:19, 28 Jul 2025 (diff | hist) Proglucagon 6,709 +565 m convert the receptor-distribution list to a table
  25. 06:17, 25 Jul 2025 (diff | hist) Peptide harm reduction 4,630 +45 m expand §The limits of this article
  26. 13:17, 10 Jul 2025 (diff | hist) Dipeptidyl peptidase-4 7,022 +554 British spelling per PP:MOS
  27. 14:45, 20 Jun 2025 (diff | hist) Enteroendocrine L cell 5,083 +435 rm the sentence implying the hormone is a drug
  28. 14:31, 15 Jun 2025 (diff | hist) Glucagon-like peptide-1 11,430 +201 m correct the second-messenger pathway named in the lead
  29. 10:07, 25 May 2025 (diff | hist) Albumin binding half-life extension 6,021 +1,149 move the trial material out of §Physiology into the compound articles
  30. 02:07, 12 Mar 2025 (diff | hist) Survodutide 4,470 +465 expand §Design and rationale
  31. 04:59, 5 Feb 2025 (diff | hist) Wuhan Wansheng Biotechnology 9,239 +27 expand §External links
  32. 21:39, 3 Feb 2025 (diff | hist) Customs seizure 2,395 ±0 ce per PP:MOS
  33. 04:24, 21 Jan 2025 (diff | hist) Peptide 4,059 ±0 add short description
  34. 20:01, 24 Dec 2024 (diff | hist) Incretin effect 5,179 +197 m close an unbalanced quotation mark
  35. 08:15, 10 Nov 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 5,459 +159 add the reference range with the assay it was established on
  36. 22:49, 20 Oct 2024 (diff | hist) Trifluoroacetate counterion 2,370 ±0 ce
  37. 15:17, 16 Oct 2024 (diff | hist) Albumin binding half-life extension 3,157 +336 m attribute the gastric-emptying effect to the study that measured it
  38. 10:33, 22 Sep 2024 (diff | hist) Gastric emptying 3,153 +373 m clarify that concentrations differ substantially between assay platforms
  39. 12:24, 19 Sep 2024 (diff | hist) Arcuate nucleus 1,271 ±0 m add a figure for the secretion time course and caption it
  40. 06:47, 1 Sep 2024 (diff | hist) GLP-1 receptor 3,714 ±0 m fix a broken wikilink
  41. 19:17, 28 Aug 2024 (diff | hist) Enteroendocrine L cell 2,621 ±0 m clarify that the receptor is expressed outside the pancreas
  42. 22:03, 18 Aug 2024 (diff | hist) Satiety signalling 1,326 ±0 add category for receptor pharmacology
  43. 02:51, 28 Jun 2024 (diff | hist) Incretin effect 1,841 ±0 the article treated a rodent finding as human physiology; corrected